… patients receiving erlotinib for adenocarcinoma in the lung. … good tumor response on this
EGFR TKI treatment, patients and … discontinuation and subsequently lung cancer progression. …

… A minority of patients with non–small-cell lung cancer (NSCLC) present with localized
disease. Treatment for early-stage disease in fit patients is focused on curative surgery. …

… low in lung SCC. The aim of this study was to evaluate the status … erlotinib treatment and
EGFR mutation in lung SCC patients. Methods: We retrospectively enrolled lung cancer patients …

… Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced
EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with …

… We investigated whether erlotinib improves clinical outcome in these patients. … patients to
receive erlotinib and 320 to receive placebo. We followed up patients until March 31, 2011. 657 …

… Patients and Methods In this randomized, cross-over, pharmacokinetic study in patients with
non–small-cell lung cancer… day period of concomitant treatment with erlotinib, with or without …

… This phase III study assessed the efficacy of vandetanib versus erlotinib in unselected patients
with advanced non–small-cell lung cancer (NSCLC) after treatment failure with one to two …

… On the basis of these findings, we did a randomised phase 3 trial to compare dacomitinib
with erlotinib in patients with advanced non-small-cell lung cancer, including patients with …

… efficacy and safety profile of erlotinib compares with CT in … phase III study comparing erlotinib
with platinum-based CT in … and 174 patients were randomly assigned to receive erlotinib or …

… , time to deterioration of patient reported symptoms (TTDS), … patients randomized to erlotinib.
Rash and diarrhea were the most frequent symptoms; 5% of patients discontinued erlotinib …